Literature DB >> 6172554

Interferon induction by lymphocytic choriomeningitis viruses correlates with maximum virulence.

S Jacobson, R M Friedman, C J Pfau.   

Abstract

Lymphocytic choriomeningitis (LCM) viruses isolated from the blood of persistently infected mice, could be clearly divided into two categories by observing the disease patterns they produced after intracerebral (i.c.) injection in a number of adult inbred and outbred mice. One type (aggressive) caused the classic pattern of convulsive death in 100% of the mice 7 to 9 days after infection, while the other (docile) caused a protracted disease with deaths occurring, if at all, 2 to 4 weeks after infection. Interferon could be detected in the serum of adult mice on the 3rd and 4th day after infection with several independently cloned aggressive, but not docile, viruses. The inability of docile virus to induce interferon was not due to poor or delayed virus replication in the brain. The aggressive pattern of disease could be provoked easily in docile virus-infected mice with the interferon inducers poly(rI) . poly(rC), tilorone hydrochloride or Newcastle disease virus. The amount of interferon produced had little effect on the mean day of death. Mice that differed over 10-fold in their serum interferon levels after LCM infection, either by genetic predisposition or by stimulation with increasing amounts of poly(rI) . poly(rC), presented almost identical patterns of mortality.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6172554     DOI: 10.1099/0022-1317-57-2-275

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Chemokine gene expression in the brains of mice with lymphocytic choriomeningitis.

Authors:  V C Asensio; I L Campbell
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Expression of alpha/beta interferons (IFN-alpha/beta) and their relationship to IFN-alpha/beta-induced genes in lymphocytic choriomeningitis.

Authors:  K Sandberg; M L Eloranta; I L Campbell
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

3.  Characterization of a nonvirulent variant of lymphocytic choriomeningitis virus.

Authors:  P R Brayton; H F Maassab
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

4.  Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response.

Authors:  J C Morrill; G B Jennings; A J Johnson; T M Cosgriff; P H Gibbs; C J Peters
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon.

Authors:  D Moskophidis; M Battegay; M A Bruendler; E Laine; I Gresser; R M Zinkernagel
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Cytotoxic T cells are induced in mice infected with lymphocytic choriomeningitis virus strains of markedly different pathogenicities.

Authors:  C J Pfau; J K Valenti; S Jacobson; D C Pevear
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

7.  Interferon system in patients with systemic juvenile chronic arthritis: in vivo and in vitro studies.

Authors:  T H Bacon; A de Vere-Tyndall; D A Tyrrell; A M Denman; B M Ansell
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

8.  Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus.

Authors:  M Kohler; B Rüttner; S Cooper; H Hengartner; R M Zinkernagel
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus and in vitro properties.

Authors:  J Anderson; J A Byrne; R Schreiber; S Patterson; M B Oldstone
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

10.  Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells.

Authors:  J F Bukowski; R M Welsh
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.